Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia
  • Macrophage activation marker neopterin: A candidate biomarker for treatment response and relapse in visceral leishmaniasis
  • Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma

RSS PRESS RELEASES

  • FIND and DNDi team up to support Malaysian MOH efforts to simplify and decentralize hepatitis C screening & treatment
  • DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients
  • Drug approved in Argentina for treatment of Chagas disease in children

RSS NEWS

  • Malaysia takes the lead on a public health approach to hepatitis C with new initiative to enhance diagnosis & treatment
  • DNDi announces new Director of Neglected Tropical Diseases
  • DNDi and GARDP Call for Nominations for Treasurer of their Boards of Directors

RSS IN THE MEDIA

  • Frankfurter Rundschau: “Forschung auch für arme Patienten”
  • Nanyang Business Daily: “国人意识低不知患病 卫生部推防C型肝炎计划”
  • The Malaysian Reserve: “MoH, FIND to develop new hep C diagnostic tests”

RSS EVENTS

  • ASTMH 2018
  • Southern African HIV Clinicians Society Conference
  • Keystone Conference 2018

RSS Scientific Articles

  • A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia
  • Macrophage activation marker neopterin: A candidate biomarker for treatment response and relapse in visceral leishmaniasis
  • Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma
  • Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Social Mission Ration 2017

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close